Anaphylactoid reactions / anaphylaxis (includes anaphylactic shock)

• Negative findings
• (2024): Anthony MS+, Diabetes Care 47(4), 712-719 ('anaphylaxis is rare with GLP-1 receptor agonists')

Cutaneous adverse reaction (includes severe cutaneous adverse drug reaction (SCAR))

• (2024): Salazar CE+, Arch Dermatol Res 316(6), 248 [REVIEW]

Thinning

• (2025): Semersky A+, Aesthet Surg J Open Forum Apr (e-Collection) ("GLP-1 Face")

Cardiotoxicity

• (2024): Ashraf MT+, Am J Ther 31(4), e483-e486 [REVIEW]

Cardiovascular adverse effect (includes major adverse cardiovascular events (MACE))

• Negative findings
• (2025): Tanashat M+, Am J Cardiovasc Drugs Apr, Online ahead of print [REVIEW]

Anorexia

• (2024): Jiao BL+, Eur Rev Med Pharmacol Sci 28(8), 3073-3084 [REVIEW]

Neurotoxicity

• (2026): Kotta A+, J Psychiatr Pract 32(3), 156-159 (1 case) (with lithium) (induction)

Psychiatric adverse effect

• (2024): Kornelius E+, Sci Rep 14(1), 24433 (association)

Suicidal ideation

• Negative findings
• (2024): Kerem L+, JAMA Pediatr Oct, Online ahead of print ("a favorable psychiatric safety profile of GLP-1 receptor agonists in adolescents")
• (2024): Ruggiero R+, Pharmaceuticals (Basel) 17(2), 147 [REVIEW] ("causality requires further investigation") (pharmacovigilance / pharmacoepidemiology)

Diabetic ketoacidosis

• (2024): Forouzanmehr B+, Naunyn Schmiedebergs Arch Pharmacol Aug, Online ahead of print [REVIEW] (association)
• (2022): Wu T+, Clin Drug Investig Sep, Online ahead of print (association)

Weight loss

• (2022): Wu T+, Clin Drug Investig Sep, Online ahead of print
• (2016): Janzen KM+, Ann Pharmacother 50(8), 656 [REVIEW]

Cholecystitis (calculous / acalculous)

• (2025): Tao C+, Front Pharmacol Jul (e-Collection) (association) (pharmacovigilance / pharmacoepidemiology)

Cholelithiasis (gallstones in the gall bladder or the bile duct)

• (2025): Tao C+, Front Pharmacol Jul (e-Collection) (association) (pharmacovigilance / pharmacoepidemiology)

Diarrhea

• (2025): Velji-Ibrahim J+, J Obes Oct (e-Collection) 8%–20% [REVIEW]
• (2017): Bettge K+, Diabetes Obes Metab 19(3), 336 [REVIEW]

Dyspepsia / functional dyspepsia (indigestion) (see also gastroparesis)

• (2024): Jiao BL+, Eur Rev Med Pharmacol Sci 28(8), 3073-3084 [REVIEW]

Gastrointestinal adverse reaction

• (2026): Sukkar GA+, Saudi J Gastroenterol Mar, Online ahead of print [REVIEW]
• (2025): Douros JD+, Front Endocrinol (Lausanne) Feb (e-Collection) [REVIEW]
• (2025): Guo H+, Obes Pillars Jan (e-Collection) [REVIEW]
• (2025): Maracle B+, Aliment Pharmacol Ther Nov, Online ahead of print [REVIEW]
• (2025): Sedenho-Prado LG+, Int J Obes (Lond) Apr, Online ahead of print [REVIEW]
• (2025): Tanashat M+, Am J Cardiovasc Drugs Apr, Online ahead of print [REVIEW]
• (2025): Zamanian N+, Eur J Pharmacol Jul, Online ahead of print [REVIEW]
• (2024): Bak M+, Acta Psychiatr Scand Jul, Online ahead of print [REVIEW]
• (2024): Zhou J+, Br J Clin Pharmacol Dec, Online ahead of print ("Glucagon-like peptide-1 receptor agonists are not recommended for use during pregnancy") (pharmacovigilance / pharmacoepidemiology)

Gastroparesis (delayed gastric emptying)

• (2026): Ahmed Z+, Gastroenterology Res 19(2), 64-73 [REVIEW] (association)
• (2026): Kang D+, Korean J Intern Med 41(3), 384-395 [REVIEW]

Hepatotoxicity / liver injury / acute liver injury / drug-induced liver injury (DILI)

• (2022): Wu T+, Clin Drug Investig Sep, Online ahead of print (association)

Nausea

• (2026): Kateel R+, Diabetes Res Clin Pract May, Online ahead of print [REVIEW]
• (2025): Velji-Ibrahim J+, J Obes Oct (e-Collection) 14%–28% [REVIEW]
• (2022): Wu T+, Clin Drug Investig Sep, Online ahead of print
• (2021): Ryan PM+, J Pediatr May, Online ahead of print [REVIEW]
• (2017): Bettge K+, Diabetes Obes Metab 19(3), 336 [REVIEW]
• (2016): Janzen KM+, Ann Pharmacother 50(8), 656 [REVIEW]

Pancreatitis / acute pancreatitis

• (2025): Mahajne J+, BMJ Case Rep 18(9), e267811 (3 cases)
• (2022): Wu T+, Clin Drug Investig Sep, Online ahead of print (association)
• (2014): Soldevila B+, Med Clin (Barc) (Spanish) 143 Suppl 2, 35 [REVIEW]

Vomiting / emesis

• (2026): Kateel R+, Diabetes Res Clin Pract May, Online ahead of print [REVIEW]
• (2025): Velji-Ibrahim J+, J Obes Oct (e-Collection) 6%–12% [REVIEW]
• (2017): Bettge K+, Diabetes Obes Metab 19(3), 336 [REVIEW]

Erectile dysfunction

• (2025): Kounatidis D+, Biomolecules Sep (e-Collection) [REVIEW] (association)
• (2025): Pourabhari Langroudi A+, Int J Impot Res 37(8), 661-667 (weak association) (pharmacovigilance / pharmacoepidemiology)

Ocular adverse effect

• (2026): Maideen NMP+, Indian J Ophthalmol Mar, Online ahead of print [REVIEW]

Optic neuropathy (includes ischemic optic neuropathy)

• (2026): Kakkar AK+, Diabetes Obes Metab Jun, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)

Otolaryngological adverse effects / otorhinolaryngological adverse effects

• (2025): Pak KY+, Otol Neurotol 46(1), 19-22 (pharmacovigilance / pharmacoepidemiology)

Nephrolithiasis (kidney stones / renal calculi)

• (2022): Wu T+, Clin Drug Investig Sep, Online ahead of print (association)

Adverse effects / adverse reactions

• (2026): Chao AM+, PLoS Med Jan (e-Collection) [REVIEW]
• (2026): Hurtado RL+, Diabetes Obes Metab Mar, Online ahead of print [REVIEW]
• (2026): Jalleh RJ+, J Clin Invest Feb (e-Collection) [REVIEW]
• (2026): Kim MK+, J Obes Metab Syndr Mar, Online ahead of print [REVIEW]
• (2026): Lee N+, Diabetes Metab Res Rev 42(4), e70163 [REVIEW] (pharmacovigilance / pharmacoepidemiology)
• (2026): Lund LC+, Diabetes Res Clin Pract May, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
• (2026): Patel D, Cureus 18(4), e107202 [REVIEW]
• (2025): Davila Diaz R+, Cureus 17(12), e99865 [REVIEW]
• (2025): Kunutsor SK+, Drugs Dec, Online ahead of print [REVIEW]
• (2025): McCall KL+, Expert Opin Drug Saf Apr, Online ahead of print [REVIEW] (pharmacovigilance / pharmacoepidemiology)
• (2024): Huang YN+, Diabetes Obes Metab Aug, Online ahead of print
• (2022): Wu T+, Clin Drug Investig Sep, Online ahead of print
• Negative findings
• (2026): Pascale S+, Ann Pharmacother Feb, Online ahead of print [REVIEW]
• (2025): Jia A+, Front Cardiovasc Med Oct (e-Collection) [REVIEW]
• (2024): Balshi A+, Mult Scler Relat Disord Dec, Online ahead of print

Adverse pregnancy outcomes

• (2024): Zhou J+, Br J Clin Pharmacol Dec, Online ahead of print (association) ("Glucagon-like peptide-1 receptor agonists are not recommended for use during pregnancy") (pharmacovigilance / pharmacoepidemiology)
• Negative findings
• (2024): Dao K+, BMJ Open 14(4), e083550 (no increased risk of pregnancy losses seen in the GLP-1 receptor agonist-exposed group versus a diabetes group and an overweight/obese reference group)

Cancer (carcinogenesis / oncogenesis / tumorigenesis)

• (2026): Li Z+, J Diabetes Res Mar (e-Collection) [REVIEW] (association) (risk factors) (pharmacovigilance / pharmacoepidemiology)
• (2022): Wu T+, Clin Drug Investig Sep, Online ahead of print (association)
• (2014): Soldevila B+, Med Clin (Barc) (Spanish) 143 Suppl 2, 35 [REVIEW]